Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting PGLYRP1 promotes anti-tumor immunity while inhibiting autoimmunity

ABSTRACT: Targeting PGLYRP1 promotes anti-tumor immunity while inhibiting autoimmunity

PROVIDER: PRJNA928763 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23255400.fastq.gz	Fastqsanger.gz
	SRR23255401.fastq.gz	Fastqsanger.gz
	SRR23255402.fastq.gz	Fastqsanger.gz
	SRR23255403.fastq.gz	Fastqsanger.gz
	SRR23255404.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 172

Similar Datasets

Targeting PGLYRP1 promotes anti-tumor immunity while inhibiting autoimmunity

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-06-09 | GSE223896 | GEO

Tonic type 2 immunity controls autoimmunity in the skin

Project description:The existence of immunoregulatory mechanisms that control autoimmunity in non-lymphoid tissues remains unclear. Through transcriptomic and lipidomic analyses, we found that psoriasis is tightly associated with a significant downregulation of fatty acid metabolism and biosynthesis pathways as well as Th2 signature genes. Among lipids-activated transcription factors, LXR and PPAR were required for fatty acid homeostasis and resistance to psoriasis in mice. STAT6 played a role in the homeostatic expression of LXR and PPARγ in the skin. Additionally, innate lymphoid cells established tonic type 2 immunity in normal skin by producing IL-13 continually. Mice lacking tonic type 2 immunity were more susceptible to psoriatic inflammation in vivo. In human skin, inhibiting tonic type 2 immunity worsened psoriasis-like inflammation and IL-17 production, while activating LXR or PPAR inhibited them. Therefore, tonic type 2 immunity is an essential tissue checkpoint that represses autoimmunity and maintains lipid homeostasis in the skin.

2024-04-08 | GSE229198 | GEO

FTO degradation targeting enhances anti-tumor immunity

Project description:FTO degradation targeting enhances anti-tumor immunity

| PRJNA1053378 | ENA

Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1

Project description:Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1

| PRJNA972474 | ENA

Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti- PD-1 resistance via targeting PD-L1

Project description:Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti- PD-1 resistance via targeting PD-L1

| PRJNA967696 | ENA

Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1

Project description:Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1

| PRJNA1117900 | ENA

Autoimmunity associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity

Project description:Autoimmunity associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity

| PRJNA1075774 | ENA

ScRNA-seq of immune cells in tumors or during EAE from Pglyrp1 KO and wildtype mice.

Project description:PGLYRP1 is highly co-expressed with known co-inhibitory molecules and might be a promising novel target for immunotherapy. Indeed, genetic deletion of PGLYRP1 in mice led to decreased tumor growth and an increased activation/effector phenotype in CD8+ T cells, suggesting an inhibitory function of PGLYRP1 in CD8+ T cells. Surprisingly, genetic deletion of PGLYRP1 strongly protected against experimental autoimmune encephalomyelitis (EAE), a model of autoimmune disease in the central nervous system (CNS). Pglyrp1-deficient myeloid cells had a defect in antigen-presentation and T cell activation, indicating that PGLYRP1 might act as a proinflammatory molecule in myeloid cells during autoimmunity. Our results highlight PGLYRP1 as a promising novel target for immunotherapy, that, when targeted, elicits a potent anti-tumor immune response while protecting against tissue inflammation and autoimmunity.

2023-06-12 | GSE223873 | GEO

Tonic type 2 immunity controls autoimmunity in the skin

Project description:Tonic type 2 immunity controls autoimmunity in the skin

| PRJNA953394 | ENA

Targeting cathepsin B by cycloastragenol enhances anti-tumor immunity via inhibiting MHC-1 degradation and promoting the presentation of tumor antigen

Project description:Targeting cathepsin B by cycloastragenol enhances anti-tumor immunity via inhibiting MHC-1 degradation and promoting the presentation of tumor antigen

| PRJNA809393 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data